The funding accelerates deployment of the first agentic medical assistant that autonomously calls patients before visits, captures structured clinical histories, and writes intake notes directly into the EHR, thereby reshaping how health systems approach the front door of care.

Continue reading→

Phoenix, Arizona, August 3, 2026: BioLab Holdings, Inc. has announced the publication of a peer-reviewed real-world evidence (RWE) study demonstrating promising clinical outcomes for its Membrane Wrap™ human amniotic tissue membrane in the treatment of complex pressure ulcers. Published in the International Journal of Tissue Repair, the multicenter pilot feasibility study evaluated Membrane Wrap™ in combination with standard of care (SOC) compared with standard wound care alone, highlighting the potential of placental-based regenerative therapies to improve healing outcomes in patients with chronic wounds. The study analyzed de-identified electronic health record data from the U.S. Wound Registry and Intellicure database, involving 182 patients across multiple healthcare settings. Results showed that 63.7% of patients treated with Membrane Wrap™ plus standard care were classified as healing or healed, compared with 48.4% of patients receiving standard care alone. The findings further strengthen BioLab’s growing body of clinical evidence supporting advanced wound care technologies designed to enhance tissue restoration and improve patient outcomes.Continue reading→

Scottsdale, AZ and Boca Raton, FL — August 4, 2026 — CND Life Sciences, a leading neurodiagnostics company advancing objective biomarker-based testing for neurodegenerative diseases, today announced the completion of growth financing led by S-Curve Partners, an operator-led healthcare investment firm focused on founder-inspired healthcare technology and diagnostics businesses. S-Curve was joined by current CND investors and shareholders, reflecting continued confidence in the Company’s commercial trajectory, expanding clinical adoption, and long-term strategic positioningContinue reading→

Share exchange establishes NanoRx as the drug delivery platform technology provider and EnduRx as the developer of use-casesContinue reading→

A new study highlights how a decade of investment in research commercialization is translating discoveries into high-impact companies.
Continue reading→

Business & Bioindustry: Arizona’s collaborative ecosystem drives discovery and growth is the cover story of the August 2026 issue of In Business Magazine – Greater Phoenix.Continue reading→

The 2027 cohort application is open. Apply by Friday, Oct. 30.

The Flinn Foundation Bioscience Entrepreneurship Program enables Arizona early-stage bioscience companies to access funding, professional support, connections, and networking opportunities. Since 2014, the Program has selected 66 companies in a competitive process to receive funding through a nonprofit partner. The 12 program cohorts have received more than $2.1 million in funding support. Continue reading→

The application is now open. Apply by Friday, Sept. 11.

The Flinn Foundation Translational Seed Grants Program funds research teams affiliated with an Arizona university, research institution, or health-care system that are advancing new products or services addressing significant clinical needs. Continue reading→

First public scientific presentation provides the biomedical engineering community with its first detailed view of the next-generation total artificial heart platformContinue reading→